Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

My thesis argues that Sanofi is a buy today. I think the driving factor of this thesis with the greatest weight to my buy ...

with an initial rollout expected for phase 3 tests of Sanofi’s multiple sclerosis meds. Here’s how the tool is designed: ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...